Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers-Reference-Cited by-同舟云学术

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

Published:2019-11 Issue:2 Volume:155 Page:262-269
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Labidi-Galy S. Intidhar,de La Motte Rouge Thibault,Derbel Olfa,Wolfer Anita,Kalbacher Elsa,Olivier Timothée,Combes Jean-Damien,Heimgartner-Hu Ketty,Tredan Olivier,Guevara Hemerson,Heudel Pierre-Etienne,Reverdy Thibaut,Bazan Fernando,Heinzelmann-Schwarz Viola,Fehr Mathias,de Castelbajac Victoire,Vaflard Pauline,Crivelli Louise,Bonadona Valerie,Viassolo Valeria,Buisson Adrien,Golmard Lisa,Rodrigues Manuel,Ray-Coquard Isabelle

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference30 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm;Kurman;Hum. Pathol.,2011

3. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology/gynecologic oncology group study;Norquist;Clin. Cancer Res.,2018

4. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group;Alsop;J. Clin. Oncol.,2012

5. Integrated genomic analyses of ovarian carcinoma;Cancer Genome Atlas Research N;Nature,2011

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Role of CA-125 Elimination Rate Constant (KELIM) in Patients with Advanced Epithelial Ovarian Cancer Who Received PARP Inhibitors;Cancers;2024-06-26

2. Olaparib maintenance therapy for platinum‐sensitive relapsed ovarian cancer at a single institution: A retrospective study;Journal of Obstetrics and Gynaecology Research;2024-05-14

3. CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study;International Journal of Molecular Sciences;2024-05-11

4. A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China;Frontiers in Oncology;2024-01-08

5. Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study;Scientific Reports;2023-07-24